Health · Medical Research · 2 hrs ago
Brazilian team develops lab platform to study immune cells against cervical cancer
Researchers in Brazil are developing a lab platform to study immune cells taken from cervical tumors.
The cells, called tumor-infiltrating lymphocytes, can enter tumors and identify features of cancer cells.
The team collects tumor samples at Hospital Municipal Vila Santa Catarina and sends them to an Einstein laboratory, where the cells are isolated and multiplied.
Early results show the cells can be multiplied, but researchers have not yet shown that they keep their ability to recognize and fight tumors.
Cervical cancer was chosen because it remains common in Brazil and some patients, especially those with advanced disease, do not respond well to available treatments.
The work could lead to another treatment option for these patients, and the same platform could support research on other cancers.
Before any patient studies, the team must test cell function and safety and get Anvisa approval; HPV vaccination and preventive screening remain important.
A Brazilian research team is developing a laboratory platform to multiply immune cells taken from cervical cancer tumors.
The project aims to study whether these tumor-infiltrating lymphocytes can help patients whose cancers do not respond well to existing treatments.
Preliminary results show the cells can be multiplied in the laboratory, but researchers still need to test whether they retain their ability to recognize and fight tumors.
Tumor samples are collected at Hospital Municipal Vila Santa Catarina and sent to an Einstein laboratory for cell isolation and multiplication.
The project is at an early stage, and patient studies would require further testing and authorization from Anvisa.
- Who
- Researchers at the Centro de Competência Embrapii Einstein em Terapias Avançadas are developing the platform.
- What
- They are multiplying tumor-infiltrating lymphocytes from cervical cancer samples to study their potential against the disease.
- When
- The project is in an initial development phase. The article was published on November 14, 2026.
- Where
- Tumor samples are collected at Hospital Municipal Vila Santa Catarina and processed at an Einstein laboratory in Brazil.
- Why
- Researchers want to assess whether the cells could help patients who do not respond well to existing treatments.
This story does not have two clearly opposing sides.
The United States approved the first therapy based on these cells for a type of skin cancer.
Tumor samples are collected at Hospital Municipal Vila Santa Catarina and sent to the Einstein laboratory, where cells are isolated and multiplied.
Researchers found that the cells can be multiplied in the laboratory.
Researchers must verify the cells’ function, assess their quality and safety, and obtain the necessary Anvisa authorizations.
- Cell type
- Tumor-infiltrating lymphocytes (TILs)
- Cancer studied
- Cervical cancer
- Sample collection site
- Hospital Municipal Vila Santa Catarina
- Project status
- Initial development phase in Brazil
- US approval
- First TIL-based therapy approved in 2024 for a type of skin cancer
What people are saying
O tumor pode apresentar proteínas do vírus que normalmente não estão presentes no organismo
A vacinação contra o HPV e os exames preventivos continuam sendo medidas importantes para reduzir o risco e identificar alterações antes que a doença avance